on SOPHiA GENETICS
SOPHiA GENETICS Reports 2025 Financial Performance and Announces CEO Transition
SOPHiA GENETICS, a leader in AI-driven precision medicine, announced its preliminary financial results for Q4 and full year 2025. The company achieved a fourth-quarter revenue of at least $21 million, a 20% increase compared to the previous year, alongside performing over 105,000 analyses on its SOPHiA DDM™ platform.
For the full year 2025, the firm reported revenues around $77 million, marking a year-over-year rise of roughly 18%. The company completed more than 391,000 analyses, setting a new record. Jurgi Camblong, CEO, expressed confidence in sustained growth for 2026 and beyond, with an expected revenue growth of 20-22% for 2026.
On the executive front, Ross Muken will succeed Camblong as CEO from July 2026, as Camblong transitions to Executive Chairman. Muken, the current President, is recognized for his strategic and leadership skills within the company.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SOPHiA GENETICS news